Jeffrey Graham

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 262 citations · Full text

First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium

Shaan Dudani, Jeffrey Graham, J. Connor Wells et al. · European Urology · 2019 · 86 citations · Full text

Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma

Bimal Bhindi, Jeffrey Graham, J. Connor Wells et al. · European Urology · 2020 · 60 citations

Urology, Surgical Oncology, Genitourinary Cancer +6

Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

Jeffrey Graham, J. Connor Wells, Frede Donskov et al. · European Urology Oncology · 2019 · 43 citations · Full text

Urology, Surgical Oncology, Genitourinary Cancer +6

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

Chris Parker, Noel W. Clarke, Adrian Cook et al. · The Lancet · 2024 · 43 citations · Full text